| Firm | Analyst |
|---|---|
| 2xIdeas | Henrik Munk-Nielsen |
| Bank of America Merrill Lynch | Lyanne Harrison |
| Barrenjoey | Saul Hadassin |
| Citi Investment Research | Mathieu Chevrier |
| CLSA | Andrew Paine |
| Evans & Partners | Sacha Krien |
| Jarden | Steve Wheen |
| Jefferies | Matt Taylor |
| J.P. Morgan | David Low |
| KeyBanc | Brett Fishbin |
| Macquarie | Christine Trinh |
| Mizuho Securities | Anthony Petrone |
| Morgans | Derek Jellinek |
| Morningstar | Shane Ponraj |
| MST Marquee | Dan Hurren |
| Needham | Michael Matson |
| Oppenheimer & Co, Inc. | Suraj Kalia |
| RBC Capital Markets | Craig Wong-Pan |
| Robert W. Baird & Co. | David Rescott |
| UBS | Laura Sutcliffe |
| William Blair & Company | Margaret Kaczor |
| Wilson HTM | Shane Storey |
| Wolfe Research | Mike Polark |
ResMed Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding ResMed Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of ResMed Inc. or its management. ResMed Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.